Published in Langenbecks Arch Surg on March 14, 2012
The effects of selected Australian snake venoms on tumour-associated microvascular endothelial cells (TAMECs) in vitro. J Venom Res (2013) 0.75
Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD)₃-tTF. ScientificWorldJournal (2013) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol (2007) 11.04
Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer (2010) 10.61
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 10.37
Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 9.77
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A (2002) 8.10
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res (2006) 6.52
Tumor angiogenesis. Adv Cancer Res (1985) 5.66
The role of angiogenesis in tumor growth. Semin Cancer Biol (1992) 5.33
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science (2006) 4.79
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol (2011) 3.44
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 3.05
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol (2009) 2.97
Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res (2010) 2.88
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol (2010) 2.84
Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science (2006) 2.78
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood (2007) 2.74
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol (2009) 2.69
Cancer without disease. Nature (2004) 2.65
Colon cancer stem cells: promise of targeted therapy. Gastroenterology (2010) 2.58
Tumour vascular targeting. Nat Rev Cancer (2005) 2.56
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist (2007) 1.94
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist (2011) 1.92
Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest (1998) 1.72
ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci (2010) 1.72
Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res (2007) 1.70
Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology (1996) 1.65
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2009) 1.43
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol (2009) 1.38
Pancreatic cancer: overview of descriptive epidemiology. Mol Carcinog (2012) 1.38
A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev (2012) 1.31
Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res (2004) 1.30
Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. J Exp Clin Cancer Res (2006) 1.20
Vascular endothelial growth factor in esophageal cancer. J Surg Oncol (2004) 1.19
Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch Surg (2009) 1.10
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol (2011) 1.09
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer (2002) 1.09
mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn (2009) 1.08
EPCs and pathological angiogenesis: when good cells go bad. Microvasc Res (2010) 1.07
Cancer stem cells and angiogenesis. Int J Dev Biol (2011) 1.06
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist (2011) 1.05
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets (2011) 1.03
Targeting angiogenesis in pancreatic cancer: rationale and pitfalls. Langenbecks Arch Surg (2008) 1.01
Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol (2010) 1.01
Targeting mTOR in cancer: renal cell is just a beginning. Target Oncol (2010) 1.01
Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc (2010) 0.98
Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol (2010) 0.97
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs (2011) 0.97
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res (2011) 0.95
Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys (2003) 0.95
Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut (2010) 0.94
Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis (2004) 0.93
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol (2011) 0.93
Cerebrovascular events after bevacizumab treatment: an early and severe complication. Neurocrit Care (2011) 0.93
Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol (2012) 0.91
Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin Transl Oncol (2011) 0.90
Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma. Oncol Rep (2011) 0.90
Stem cells, quiescence and rectal carcinoma: an unexplored relationship and potential therapeutic target. Br J Cancer (2011) 0.89
Anti-angiogenic agents in pancreatic cancer: a review. Anticancer Agents Med Chem (2011) 0.89
Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer (2010) 0.89
Combination therapy for renal cell cancer: what are possible options? Oncology (2011) 0.86
Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab. Clin Cancer Res (2009) 0.86
Liver cancer: Targeted future options. World J Hepatol (2011) 0.83
Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer? Clin Transl Oncol (2010) 0.82
Latest developments in targeted therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther (2010) 0.80
Classification and toxicities of vascular disrupting agents. Clin Lung Cancer (2011) 0.78
[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results]. Bull Cancer (2011) 0.78
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs (2011) 0.77
Angiogenesis inhibitors: implications for combination with conventional therapies. Curr Pharm Des (2010) 0.77
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet (2011) 3.54
Temporary intraoperative porto-caval shunt: useless or beneficial in piggy back liver transplantation? Transpl Int (2012) 2.17
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer (2002) 2.12
The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int (2007) 2.10
Involving Medical Students in Informed Consent: A Pilot Study. World J Surg (2015) 1.97
Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int (2007) 1.87
Down-regulation of the homeodomain factor Cdx2 in colorectal cancer by collagen type I: an active role for the tumor environment in malignant tumor progression. Cancer Res (2004) 1.84
Blumgart anastomosis for pancreaticojejunostomy minimizes severe complications after pancreatic head resection. Br J Surg (2009) 1.71
Overture for growth hormone: requiem for interleukin-6? Crit Care Med (2007) 1.69
beta-Lactamase activity in slow-growing nonpigmented mycobacteria and their sensitivity to certain beta-lactam antibiotics. Tubercle (1980) 1.60
Effects of phenylephrine on the sublingual microcirculation during cardiopulmonary bypass. Br J Anaesth (2009) 1.56
[Operative techniques and outcomes in metabolic surgery: sleeve gastrectomy]. Zentralbl Chir (2009) 1.54
Techniques and results of laparoscopic antireflux surgery in Germany. Surg Endosc (2005) 1.49
Forced air surface rewarming in patients with severe accidental hypothermia. Resuscitation (1999) 1.46
Effects of epinephrine on intestinal oxygen supply and mucosal tissue oxygen tension in pigs. Crit Care Med (2001) 1.45
Rifampin and Triclosan but not silver is effective in preventing bacterial infection of vascular dacron graft material. Eur J Vasc Endovasc Surg (2003) 1.44
The challenge of pancreatic anastomosis. Langenbecks Arch Surg (2008) 1.41
[Cyberknife surgery with a radio-scalpel: a new treatment option for patients with unresectable metastases]. Zentralbl Chir (2010) 1.41
Inotropic treatment and intestinal mucosal tissue oxygenation in a model of porcine endotoxemia. Crit Care Med (1997) 1.40
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev (2007) 1.38
Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res (2008) 1.35
EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res (2009) 1.33
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol (2013) 1.29
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res (2004) 1.28
Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation (2008) 1.22
Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions (1977) 1.20
Vascular endothelial growth factor in esophageal cancer. J Surg Oncol (2004) 1.19
Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling. Oncogene (2008) 1.19
Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood (2005) 1.17
Cancer stem cells: how can we target them? Curr Med Chem (2008) 1.17
Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer (2003) 1.16
17 beta-Estradiol normalizes immune responses in ovariectomized females after trauma-hemorrhage. Am J Physiol Cell Physiol (2001) 1.16
EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem (2009) 1.15
Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol (2010) 1.14
Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urol Oncol (2009) 1.14
In vivo characterization of the unorthodox BvgS two-component sensor protein of Bordetella pertussis. J Mol Biol (1995) 1.13
4.3 μm quantum cascade detector in pixel configuration. Opt Express (2016) 1.12
Influence of hospital volume on local recurrence and survival in a population sample of rectal cancer patients. Eur J Surg Oncol (2005) 1.11
Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch Surg (2009) 1.10
Effect of combining nicotinamide as a PARS-inhibitor with selective iNOS blockade during porcine endotoxemia. Intensive Care Med (2003) 1.10
Laparoscopic colonoscopic rendezvous procedures for the treatment of polyps and early stage carcinomas of the colon. Int J Colorectal Dis (2007) 1.09
Acute pneumatosis cystoides intestinalis following allogeneic transplantation -- the surgeon's dilemma. Bone Marrow Transplant (2002) 1.09
Pain perception during self-reported distress and calmness in patients with borderline personality disorder and self-mutilating behavior. Psychiatry Res (2000) 1.09
Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther (2002) 1.08
[Current developments in liver transplantation in Germany: MELD-based organ allocation and incentives for transplant centres]. Z Gastroenterol (2011) 1.07
Transoral diverticulostomy with a modified Endo-Gia stapler: results after 4 years of experience. Surg Endosc (2006) 1.07
[Primary midline closure after excision of a pilonidal sinus is associated with a high recurrence rate]. Chirurg (2003) 1.05
Testosterone: the crucial hormone responsible for depressing myocardial function in males after trauma-hemorrhage. Ann Surg (1998) 1.05
Flutamide: a novel agent for restoring the depressed cell-mediated immunity following soft-tissue trauma and hemorrhagic shock. Shock (1997) 1.04
Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res (2004) 1.02
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol (2010) 1.02
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology (2008) 1.00
Genetically engineered stem cells for therapeutic gene delivery. Curr Gene Ther (2007) 0.99
[Postoperative femoral fractures in total endoprosthesis of the hip joint]. Unfallheilkunde (1984) 0.99
H1 + H2-receptor antagonists for premedication in anaesthesia and surgery: a critical view based on randomized clinical trials with Haemaccel and various antiallergic drugs. Agents Actions (1980) 0.99
Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg (2007) 0.98
Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer. Stem Cells Dev (2012) 0.97
Do female sex steroids adversely or beneficially affect the depressed immune responses in males after trauma-hemorrhage? Arch Surg (2000) 0.97
The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J Cell Biochem (2007) 0.97
Risk factors for surgical complications in distal pancreatectomy. Am J Surg (2010) 0.96
Adverse tissue reactions to wear particles from Co-alloy articulations, increased by alumina-blasting particle contamination from cementless Ti-based total hip implants. A report of seven revisions with early failure. J Bone Joint Surg Br (2002) 0.96
Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res (2010) 0.96
[Prevalence of sleep disorders in school children between 11 and 15 years of age]. Wien Klin Wochenschr (2001) 0.96
Long-term results after surgical treatment of nonparasitic hepatic cysts. Am J Surg (2010) 0.95
Surgical management of splenic echinococcal disease. Eur J Med Res (2009) 0.95
Intracellular polyamine levels of intestinal epithelial cells in inflammatory bowel disease. Inflamm Bowel Dis (2004) 0.95
Collagen sandwich culture affects intracellular polyamine levels of human hepatocytes. Cell Prolif (2002) 0.94
Hepatic progenitor cells from adult human livers for cell transplantation. Gut (2008) 0.93
Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res (2010) 0.93
Expression of augmenter of liver regeneration (ALR) in human liver cirrhosis and carcinoma. Histopathology (2005) 0.93
Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation. PLoS One (2013) 0.93
Laparoscopic mesh repair of incisional hernia: an alternative to the conventional open repair? Hernia (2007) 0.92
18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging (2011) 0.92
[1995 consensus guidelines for cholesterol. Society of Physicians in Vienna]. Wien Klin Wochenschr (1995) 0.91
Quality of life 2-10 years after combined treatment for advanced oral and oropharyngeal cancer. Int J Oral Maxillofac Surg (2002) 0.91
Immune dysfunction following trauma-haemorrhage: influence of gender and age. Cytokine (2000) 0.91
Health care in Austria. Universal access, national health insurance, and private health care. JAMA (1993) 0.91
Dehydroepiandrosterone restores immune function following trauma-haemorrhage by a direct effect on T lymphocytes. Cytokine (1999) 0.91
Comparison of lactated Ringer's, gelatine and blood resuscitation on intestinal oxygen supply and mucosal tissue oxygen tension in haemorrhagic shock. Br J Anaesth (2006) 0.91
Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas. Invest Radiol (2012) 0.90
Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. Onkologie (2005) 0.90
Squamous carcinoma of the external ear. Am J Surg (1983) 0.90
Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis (2007) 0.89
Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer? Drug Resist Updat (2006) 0.89
Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer (2010) 0.89
Laparoscopic management of a small bowel perforation caused by a toothpick. Surg Endosc (2004) 0.89
Acute ischemia of the upper extremity: long-term results following thrombembolectomy with the Fogarty catheter. Langenbecks Arch Surg (2001) 0.88
Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int (2005) 0.88
Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study. AJR Am J Roentgenol (2012) 0.88